SAMHSA estimates that 7.6 million of 47.2 million people classified as needing substance use treatment received it in 2025, while the treatment rate among 18-to-25-year-olds was only 9.6%.
MERIDA, YUCATAN / ACCESS Newswire / November 2, 2026 / TranquilHearts Private Mexico Rehab & Addiction Treatment has analyzed substance use treatment access in the United States, drawing on newly released federal data showing a significant gap between the number of people classified as needing treatment and those who actually received it.
According to the Substance Abuse and Mental Health Services Administration (SAMHSA, 2025 NSDUH), 47.2 million people aged 12 or older needed substance use treatment during 2025, yet only 7.6 million, or 16.0%, received it. The analysis underscores why families searching for treatment options increasingly evaluate facilities across borders and treatment modalities, comparing clinical credentials, evidence-based practices, and continuity-of-care models regardless of location.
The remaining 39.6 million people, or 84.0%, did not receive treatment for substance use in 2025 (SAMHSA, 2025 NSDUH) despite meeting the survey’s criteria for needing it. This treatment gap reflects not a shortage of facilities but rather a combination of barriers: cost, availability, readiness, stigma, and structural gaps in care continuity.
For families navigating treatment decisions, understanding this national context and learning to evaluate programs based on clinical quality rather than proximity becomes essential.
The Treatment-Access Crisis and Age-Specific Gaps
The treatment-receipt deficit is not uniform across age groups. Young adults aged 18 to 25 had the lowest treatment-receipt rate at 9.6%, representing only 845,000 people receiving treatment despite an estimated 8.8 million in that age group classified as needing it.
By contrast, adolescents aged 12 to 17 had a 22.8% treatment-receipt rate, and adults aged 26 or older had a 17.1% rate (SAMHSA, Highlights for the 2025 National Survey on Drug Use and Health). This age-related gap is particularly relevant for families with young adult members struggling with substance use, as it indicates that this population faces the highest barriers to accessing treatment.
Beyond the “needed treatment” measure, an additional measure of unmet need emerges from data on diagnosed substance use disorders. It is estimated that 44.6 million people aged 12 or older with a past-year substance use disorder, 38.5 million, or 86.4%, did not receive substance use treatment or other services for their substance use (SAMHSA, 2025 NSDUH Highlights).
This figure uses a clinically narrower denominator than “needed treatment” and reflects people meeting diagnostic criteria for SUD who received neither clinical intervention nor peer support services.
Treatment Settings and Modalities
When treatment does occur, it takes multiple forms. Among 7.6 million people who received substance use treatment in 2025, 4.4 million received outpatient services, 3.6 million received telehealth treatment, and 2.2 million received inpatient treatment (SAMHSA, 2025 NSDUH blog). These categories can overlap; a person may have received both outpatient and telehealth care, for example, so they should not be summed as representing distinct populations.
The predominance of outpatient and telehealth treatment reflects both practical accessibility and cost considerations. Inpatient facilities, including residential rehab centers, represent a smaller but important segment of the treatment landscape.
The 2.2 million people who received inpatient treatment represent roughly 29% of the 7.6 million who received any treatment (SAMHSA, 2025 annual blog), highlighting that the majority of treatment occurs in non-residential settings.
Perceived Barriers to Treatment
Among people who perceived an unmet need for treatment, multiple barriers emerged. 82.5% reported believing they should handle alcohol or drug use on their own, 68.4% said they were not ready to stop or cut back, 67.7% reported not being ready to start treatment, 54.3% cited not having enough time, and 41.4% expressed concern about what others would think or say (SAMHSA, 2025 NSDUH). These responses indicate that readiness, social stigma, and logistical factors rival cost and availability as barriers to treatment engagement.
This barrier profile informs how families should approach treatment selection. Longer-stay residential programs can address readiness and motivation by providing structured time, skills development, and psychoeducation. Programs with strong family involvement and continuing-care coordination can help overcome social isolation and support continuity after initial treatment. Facilities operating in settings with lower stigma may attract patients who hesitate due to public perception concerns.
Mortality Context: 2025 Overdose Deaths
U.S. overdose mortality remained elevated in 2025. The CDC reported provisional data of 69,973 overdose deaths in 2025, down approximately 14% from 81,313 in 2024 (CDC National Center for Health Statistics, released May 2026). While this decline signals some progress, the number remains substantially higher than pre-pandemic levels and underscores the ongoing urgency of expanding treatment access and effectiveness.
How to Evaluate Treatment Programs
When selecting a substance use treatment program, SAMHSA recommends examining several key dimensions. Families should verify that any program holds relevant licensing and accreditation, employs evidence-based practices supported by research, offers appropriate medication-assisted treatment options, ensures qualified and credentialed staff, involves family members in care planning and support, and provides structured continuing-care and aftercare support (SAMHSA, Quality Treatment for Mental Health, Drugs and Alcohol, Current Guidance).
For programs operating outside the United States, additional verification becomes important. Prospective patients and families should independently confirm the facility’s local licensure and regulatory standing. They should verify staff credentials against professional registries in the operating country, review the facility’s protocols for medical and psychiatric emergencies, and understand how care continuity is managed after treatment completion.
It’s also crucial to obtain a complete accounting of what services are included in quoted monthly costs, clarify what happens if a patient requires a higher level of medical care, and review the facility’s policies on family communication and involvement.
Methodology
Synthesized findings from SAMHSA’s 2025 National Survey on Drug Use and Health annual release, highlights, and detailed tables (SAMHSA, 2025 NSDUH, released July 2026), supplemented by CDC provisional 2025 overdose-mortality data (CDC NCHS, released May 2026) and SAMHSA guidance on quality treatment.
The primary treatment figures are nationally weighted population estimates from a 2025 NSDUH sample of approximately 60,450 respondents aged 12 or older (SAMHSA, 2025 NSDUH Detailed Tables). The analysis distinguishes people classified as needing substance use treatment (47.2 million) from people meeting criteria for a past-year substance use disorder (44.6 million); these are related but separate denominators and must not be merged. Treatment modalities are kept separate because categories can overlap. No proprietary TranquilHearts clinical outcomes, patient survey, completion-rate, or relapse-rate data were used.
Frequently Asked Questions
What does it mean that only 16% of people who needed substance use treatment received it?
SAMHSA’s 2025 data indicate 47.2 million people aged 12 or older met the survey criteria for needing substance use treatment. Of those, only 7.6 million, or 16.0%, received treatment during the year. This figure is a nationally weighted population estimate, not a count of individual treatment facilities or TranquilHearts patients. The gap reflects multiple barriers like cost, availability, readiness, stigma, and continuity-of-care gaps, rather than a single cause.
Which age group had the lowest treatment-receipt rate?
Young adults aged 18 to 25 had the lowest treatment-receipt rate at 9.6%, compared with 22.8% for adolescents aged 12 to 17 and 17.1% for adults aged 26 or older. Among the estimated 8.8 million young adults classified as needing treatment, only 845,000 received it. TranquilHearts does not speculate about the reasons for this age-specific gap without additional research.
Does substance use treatment always mean residential or inpatient rehab?
Treatment for substance use occurs in multiple settings. Of the 7.6 million people who received treatment in 2025, 4.4 million received outpatient services, 3.6 million received telehealth treatment, and 2.2 million received inpatient care. Outpatient and telehealth options serve the majority of people receiving treatment. Residential or inpatient programs represent one option within a broader spectrum of care.
What should families compare when choosing an addiction-treatment program?
Families should refer to SAMHSA’s quality checklist: licensing and accreditation status, use of evidence-based therapeutic practices, availability of medication-assisted treatment options, qualified and credentialed clinical staff, integration of family members in treatment planning and ongoing support, and structured continuing-care and aftercare support for the transition after treatment completion. When considering a program outside the United States, verify local licensure, staff credentials, emergency protocols, continuity-of-care arrangements, total cost accounting, and escalation procedures for medical complexity.
Why is the treatment gap important for families considering residential rehab?
The 84% gap in treatment receipt demonstrates that access barriers extend beyond availability. Even as residential options expand, readiness, stigma, cost, and continuity of care remain significant obstacles. Residential programs structured to address readiness through things like extended stays supporting habit formation, family involvement, skills development, and aftercare coordination can help overcome specific barriers. Understanding these barriers helps families evaluate whether a particular program’s model aligns with their needs.
About TranquilHearts Private Luxury Rehab & Addiction Treatment Mexico
TranquilHearts Private Mexico Rehab & Addiction Treatment, founded in 2022 and based in Merida, Yucatan, provides residential addiction-treatment services. The facility is positioned as an affordable luxury rehabilitation option with clinical staffing, extended-stay availability, skills development, and recovery-focused support.
TranquilHearts Private Mexico Rehab & Addiction Treatment
Contact: Kasper
Email: info@tranquilheartsrehab.com
Location: Merida, Yucatan
SOURCE: TranquilHearts Private Mexico Rehab & Addiction Treatment
View the original press release on ACCESS Newswire
Media gallery
